Kane Biotech Inc.
KNE.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 298.60K | 403.70K | 1.34M | 1.77M | 1.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 298.60K | 403.70K | 1.34M | 1.77M | 1.52M |
| Cost of Revenue | 300.30K | 473.10K | 994.00K | 1.13M | 881.80K |
| Gross Profit | -1.60K | -69.30K | 344.10K | 640.50K | 640.60K |
| SG&A Expenses | 1.41M | 1.27M | 1.71M | 2.33M | 2.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.15M | 2.39M | 3.38M | 4.42M | 4.24M |
| Operating Income | -1.85M | -1.99M | -2.04M | -2.65M | -2.72M |
| Income Before Tax | -2.01M | -2.32M | -2.37M | -3.01M | -3.27M |
| Income Tax Expenses | -77.50K | -936.00K | -936.00K | -936.00K | -936.00K |
| Earnings from Continuing Operations | -1.93 | -1.38 | -1.44 | -2.07 | -2.33 |
| Earnings from Discontinued Operations | -- | -936.00K | -882.60K | 6.73M | 6.80M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.93M | -2.32M | -2.32M | 4.66M | 4.47M |
| EBIT | -1.85M | -1.99M | -2.04M | -2.65M | -2.72M |
| EBITDA | -1.73M | -1.85M | -1.94M | -2.54M | -2.58M |
| EPS Basic | -0.01 | -0.02 | -0.02 | 0.03 | 0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | 0.02 | 0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 833.84M | 757.01M | 561.47M | 530.80M | 512.59M |
| Average Diluted Shares Outstanding | 851.33M | 774.50M | 578.96M | 556.46M | 538.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |